BryanJohnMcColganMD
Endocrinology • Oakland, CALipid Metabolism
Endocrionologist | Clinical Research | Digital Health
Dr. McColgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1270 Excelsior Avenue
Oakland, CA 94610
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 2014 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2011 - 2014
Columbia University Vagelos College of Physicians and SurgeonsClass of 2011
Certifications & Licensure
NY State Medical License 2013 - 2025
CA State Medical License 2014 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Member Gold Humanism Honor Society, 2011
- Member Alpha Omega Alpha Honor Society, 2011
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Jun 13
- Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 26
- Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis Start of enrollment: 2016 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 117 citationsSimtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J. Muir, Cynthia Levy, Harry L.A. Janssen, Aldo J. Montano-Loza, Mitchell L. Shiffman
Hepatology. 2019-02-01 - 149 citationsAcetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.Eric Lawitz, Angie Coste, Fred Poordad, Naim Alkhouri, Nicole Loo
Clinical Gastroenterology and Hepatology. 2018-12-01 - 225 citationsGS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver DiseaseRohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric Lawitz
Gastroenterology. 2018-11-01
Professional Memberships
- Fellow
External Links
- Online Portfoliohttp://www.bryanmccolgan.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
